T1	Participants 270 316	patients with CKD, including dialysis patients
T2	Participants 495 560	patients with CKD to 20 mg simvastatin plus 10 mg ezetimibe daily
T3	Participants 833 892	2353 SHARP participants who had functioning vascular access
